Flag of the European Union EU Clinical Trials Register Help

Clinical trials for placebo treatment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10,657 result(s) found for: placebo treatment. Displaying page 373 of 533.
    «« First « Previous 369  370  371  372  373  374  375  376  377  Next» Last»»
    EudraCT Number: 2016-000912-13 Sponsor Protocol Number: 203168 Start Date*: 2016-08-30
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in s...
    Medical condition: subjects with moderate to severe rheumatoid arthritis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10039076 Rheumatoid arthritis and other inflammatory polyarthropathies LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002046-20 Sponsor Protocol Number: IOVHN12012 Start Date*: 2012-05-28
    Sponsor Name:ISTITUTO ONCOLOGICO VENETO
    Full Title: Role of SAMITAL in prevention and treatment of oral mucositis in patients treated with chemo-radiation (CT/RT)for head-and-neck squamous cell carcinomas. A double-blind, Phase 2 placebo controlled,...
    Medical condition: Head-and-neck cancer (Squamous cell carcinomas)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002176-83 Sponsor Protocol Number: SNP-S-01 Start Date*: 2015-04-01
    Sponsor Name:Clinirx Tangent Research
    Full Title: A randomized trial administering Sodium Nitroprusside vs. placebo as add-on to antipsychotics in patients with schizophrenia
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006129-29 Sponsor Protocol Number: MSC-1001 Start Date*: 2009-11-03
    Sponsor Name:MorphoSys AG
    Full Title: A multicentre, randomized, double-blind, placebo-controlled study to evaluate the safety, preliminary clinical activity and immunogenicity of multiple doses of MOR103 administered intravenously to ...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) BG (Completed) PL (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2008-003966-25 Sponsor Protocol Number: DEPOPA Start Date*: 2008-12-23
    Sponsor Name:Universität Mainz, Klinik und Poliklinik für Neurologie
    Full Title: Double-blind, placebo controlled, randomised, monocenter cross-over studie to evaluate the effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome compared t...
    Medical condition: Effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064016 Nocturnal polyuria LLT
    9.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004981-13 Sponsor Protocol Number: TIDE-11-10 Start Date*: 2012-02-02
    Sponsor Name:Helsinn Healthcare SA
    Full Title: Phase II, Double-blind, Randomized, Two-stage, Placebo-controlled Proof of Concept Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide (ZP184...
    Medical condition: Chemotherapy Induced Diarrhea
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10057013 Diarrhea post chemotherapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-000292-15 Sponsor Protocol Number: S241-GB-10 Start Date*: 2006-03-13
    Sponsor Name:Stiefel Laboratories Maidenhead Ltd.
    Full Title: A Phase II, Single-Centre, Randomised,Double-Blind, Parallel Group, CPO Solution, Dose Range Finding Study in Subjects with Seborrhoeic Dermatitis of the Scalp
    Medical condition: Seborrhoeic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039793 Seborrhoeic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001396-33 Sponsor Protocol Number: EPA-COV-001 Start Date*: 2020-11-13
    Sponsor Name:SLA Pharma (UK) Ltd [...]
    1. SLA Pharma (UK) Ltd
    2. KD Swiss GmbH
    Full Title: A randomised, double-blind, placebo-controlled study of eicosapentaenoic acid (EPA-FFA) gastro-resistant capsules to treat hospitalised subjects with confirmed SARS-CoV-2
    Medical condition: SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-006562-15 Sponsor Protocol Number: FFU111439 Start Date*: 2008-03-28
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110m...
    Medical condition: Perennial Allergic Rhinitis (PAR) in adults and children of 12 years and older.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034382 Perennial allergic rhinitis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) HU (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024254-11 Sponsor Protocol Number: CF101-301KCS Start Date*: 2011-03-30
    Sponsor Name:Can-Fite BioPharma, Ltd
    Full Title: A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients with Moderate-to-Severe Dry Ey...
    Medical condition: Moderate-to-severe Dry Eye disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10013774 Dry eye PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-000438-21 Sponsor Protocol Number: 750201.01.035 Start Date*: 2012-10-17
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Multi-center, double-blind, placebo-controlled, randomized phase III study to prove the efficacy, safety and tolerability of Silexan (WS®1265) in patients with mixed anxiety and depressive disorder...
    Medical condition: mixed anxiety and depressive disorder (ICD-10, F41.2)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10027741 Mixed anxiety & depressive LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001183-41 Sponsor Protocol Number: D5899C00002 Start Date*: 2005-02-14
    Sponsor Name:AstraZeneca AB
    Full Title: A 6-month, double-blind, double-dummy, randomised, parallel group, multicenter, efficacy and safety study of Symbicort® pMDI 2x160/4.5μg and 2x80/4.5μg bid compared to Formoterol Turbuhaler, Budes...
    Medical condition: This is an application for a phase III study to be conducted in COPD patients.
    Disease: Version SOC Term Classification Code Term Level
    10010952
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-000032-27 Sponsor Protocol Number: GUP05007 Start Date*: 2005-10-19
    Sponsor Name:ISTITUTO NEUROLOGICO CARLO BESTA
    Full Title: MULTICENTRE RANDOMISED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF LONG-TERM ASCORBIC ACID TREATMENT IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A CMT-TRIAAL CMT-TRial Italian with Ascorbic Acid Long term
    Medical condition: Charcot-Marie-Tooth disease type 1A CMT1A
    Disease: Version SOC Term Classification Code Term Level
    6.1 10034606 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011881-27 Sponsor Protocol Number: ADAM Start Date*: Information not available in EudraCT
    Sponsor Name:University Medical Center of the Johannes Gutenberg-University Mainz
    Full Title: Changes of cerebral spinal fluid APPSα levels under oral therapy with acitretin 30 mg daily in patients with mild to moderate Alzheimer’s disease: a multicenter prospective randomised placebo-contr...
    Medical condition: Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003373-10 Sponsor Protocol Number: M/34273/47 Start Date*: 2014-03-18
    Sponsor Name:ALMIRALL S.A.
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, 2 PERIOD CROSSOVER CLINICAL STUDY TO ASSESS THE EFFECT OF ACLIDINIUM BROMIDE 400 ΜCG BID ON COPD SYMPTOMS AND SLEEP QUALITY AFTER 3 WEEKS OF TREATMENT IN PATIENT...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015170-35 Sponsor Protocol Number: 5137 Start Date*: 2012-01-27
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Multicentre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated with Parkinson's Disease (MUSTARDD-PD)
    Medical condition: Parkinson's disease with mild dementia (PDD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005602-23 Sponsor Protocol Number: SCO104925 Start Date*: 2006-03-22
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease (COPD) in a Randomized, Double-Blind, Placebo-Controlled Study of Treatment with Fluticasone Propionate/Salmeter...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender:
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2005-006026-28 Sponsor Protocol Number: A3481066 Start Date*: 2006-09-25
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: Randomized, Double-Blind Study of the morphine-sparing efficacy and safety of Parecoxib sodium 40 mg i.v. followed by 20 mg i.v. every 12 hours in the treatment of pain following radical prostatectomy
    Medical condition: Patients who are scheduled to undergo routine radical prostatectomy performed under a standardized regimen of general anesthesia, and who are expected to experience moderate to severe postsurgical ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10054711 Postoperative pain LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-008339-27 Sponsor Protocol Number: A0081107 Start Date*: 2009-05-07
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY10017
    Full Title: A 17-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER TRIAL OF PREGABALIN FOR THE TREATMENT OF CHRONIC CENTRAL NEUROPATHIC PAIN AFTER SPINAL CORD INJURY
    Medical condition: Chronic Central Neuropathic Pain after Spinal Cord Injury.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-005442-23 Sponsor Protocol Number: 411-LY-08-01-0000 Start Date*: 2009-02-19
    Sponsor Name:Leyh Pharma GmbH
    Full Title: Evaluation of the efficacy and safety of nose spray containing 3% silver protein diacetyl tannate (SEAT) in patients with uncomplicated viral rhinitis. A placebo-controlled, randomized, multicentri...
    Medical condition: treatment of uncomplicated rhinal infections
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064948 Viral rhinitis LLT
    9.1 10066743 Acute rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 369  370  371  372  373  374  375  376  377  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 12:26:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA